




Instance: composition-en-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: CompositionUvEpi
Title: "Composition for cancidas Package Leaflet"
Description:  "Composition for cancidas Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/01/196/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpad129f06143be4f32271a42d5b4c5f85)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cancidas"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol type="1">
<li>What Cancidas is and what it is used for</li>
<li>What you need to know before you are given Cancidas</li>
<li>How to use Cancidas</li>
<li>Possible side effects</li>
<li>How to store Cancidas</li>
<li>Contents of the pack and other information</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. What cancidas is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cancidas is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cancidas is Cancidas contains a medicine called caspofungin.
This belongs to a group of medicines called anti-fungals. What Cancidas
is used for Cancidas is used to treat the following infections in
children, adolescents and adults:</p>
<ul>
<li>serious fungal infections in your tissues or organs (called invasive
candidiasis ). This infection is caused by fungal (yeast) cells called
Candida. People who might get this type of infection include those who
have just had an operation or those whose immune systems are weak. Fever
and chills that do not respond to an antibiotic are the most common
signs of this type of infection.</li>
<li>fungal infections in your nose, nasal sinuses or lungs (called
invasive aspergillosis ) if other anti-fungal treatments have not worked
or have caused side effects. This infection is caused by a mould called
Aspergillus. People who might get this type of infection include those
having chemotherapy, those who have had a transplant and those whose
immune systems are weak.</li>
<li>suspected fungal infections if you have a fever and a low white cell
count that have not improved on treatment with an antibiotic. People who
are at risk of getting a fungal infection include those who have just
had an operation or those whose immune systems are weak. How Cancidas
works Cancidas makes fungal cells fragile and stops the fungus from
growing properly. This stops the infection from spreading and gives the
body s natural defences a chance to completely get rid of the
infection.</li>
</ul>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Cancidas</p>
<ul>
<li>if you are allergic to caspofungin or any of the other ingredients
of this medicine (listed in section 6). If you are not sure, talk to
your doctor, nurse or pharmacist before you are given your medicine.
Warnings and precautions Talk to your doctor, nurse or pharmacist before
you are given Cancidas if:</li>
<li>you are allergic to any other medicines</li>
<li>you have ever had liver problems - you might need a different dose
of this medicine</li>
<li>you are already taking cyclosporin (used to help prevent organ
transplant rejection or to suppress your immune system) - as your doctor
may need to run extra blood tests during your treatment.</li>
<li>if you have ever had any other medical problem. If any of the above
applies to you (or you are not sure), talk to your doctor, nurse or
pharmacist before you are given Cancidas. Cancidas may also cause
Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome
(SJS) and toxic epidermal necrolysis (TEN). Other medicines and Cancidas
Please tell your doctor, nurse or pharmacist if you are taking, have
recently taken or might take any other medicines. This includes
medicines obtained without a prescription, including herbal medicines.
This is because Cancidas can affect the way some other medicines work.
Also, some other medicines can affect the way Cancidas works. Tell your
doctor, nurse or pharmacist if you are taking any of the following
medicines:</li>
<li>cyclosporin or tacrolimus (used to help prevent organ transplant
rejection or to suppress your immune system) as your doctor may need to
run extra blood tests during your treatment</li>
<li>some HIV medicines such as efavirenz or nevirapine</li>
<li>phenytoin or carbamazepine (used for the treatment of seizures)</li>
<li>dexamethasone (a steroid)</li>
<li>rifampicin (an antibiotic). If any of the above apply to you (or you
are not sure), talk to your doctor, nurse or pharmacist before you are
given Cancidas. Pregnancy and breast-feeding Ask your doctor for advice
before taking any medicine, if you are pregnant or breast-feeding or
think you are pregnant.</li>
<li>Cancidas has not been studied in pregnant women. It should be used
in pregnancy only if the potential benefit justifies the potential risk
to the unborn baby.</li>
<li>Women given Cancidas should not breast-feed. Driving and using
machines There is no information to suggest that Cancidas affects your
ability to drive or operate machinery. Cancidas contains sodium This
medicine contains less than 1 mmol sodium (23 mg) per vial, that is to
say essentially sodium-free .</li>
</ul>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cancidas will always be prepared and given to you by a healthcare
professional. You will be given Cancidas:</p>
<ul>
<li>once each day</li>
<li>by slow injection into a vein (intravenous infusion)</li>
<li>over about 1 hour. Your doctor will determine the duration of your
treatment and how much Cancidas you will be given each day. Your doctor
will monitor how well the medicine works for you. If you weigh more than
80 kg, you may need a different dose. Children and adolescents The dose
for children and adolescents may differ from the adult dose. If you have
been given more Cancidas than you should Your doctor will decide how
much Cancidas you need and for how long each day. If you are worried
that you may have been given too much Cancidas, tell your doctor or
nurse straight away. If you have any further questions on the use of
this medicine, ask your doctor, nurse or pharmacist.</li>
</ul>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although
not everybody gets them. Tell your doctor or nurse straight away if you
notice any of the following side effects you may need urgent medical
treatment:</p>
<ul>
<li>rash, itching, feeling warm, swelling of your face, lips or throat
or difficulty breathing - you may be having a histamine reaction to the
medicine.</li>
<li>difficulty breathing with wheezing or a rash that gets worse - you
may be having an allergic reaction to the medicine.</li>
<li>cough, serious breathing difficulties - if you are an adult and have
invasive aspergillosis you may be experiencing a serious respiratory
problem that could result in respiratory failure.</li>
<li>rash, skin peeling, mucous membrane sores, hives, large areas of
peeling skin. As with any prescription medicine, some side effects may
be serious. Ask your doctor for more information. Other side effects in
adults include: Common: may affect up to 1 in 10 people:</li>
<li>Decreased haemoglobin (decreased oxygen carrying substance in the
blood), decreased white blood cells</li>
<li>Decreased blood albumin (a type of protein) in your blood, decreased
potassium or low potassium levels in the blood</li>
<li>Headache</li>
<li>Inflammation of the vein</li>
<li>Shortness of breath</li>
<li>Diarrhoea, nausea or vomiting</li>
<li>Changes in some laboratory blood tests (including increased values
of some liver tests)</li>
<li>Itching, rash, skin redness or sweating more than usual</li>
<li>Joint pain</li>
<li>Chills, fever</li>
<li>Itching at the injection site. Uncommon: may affect up to 1 in 100
people:</li>
<li>Changes in some laboratory blood tests (including disease of blood
clotting, platelets, red blood cells and white blood cells)</li>
<li>Loss of appetite, increase in amount of body fluid, imbalance of
salt in the body, high sugar level in the blood, low calcium level in
the blood, increase calcium level in the blood, low magnesium level in
the blood, increase in acid level in the blood</li>
<li>Disorientation, feeling nervous, being unable to sleep</li>
<li>Feeling dizzy, decreased feeling or sensitivity (especially in the
skin), shaking, feeling sleepy, change in the way things taste, tingling
or numbness</li>
<li>Blurred vision, increase in tears, swollen eyelid, yellowing of the
whites of the eyes</li>
<li>Sensation of fast or irregular heartbeats, rapid heartbeat,
irregular heartbeat, abnormal heart rhythm, heart failure</li>
<li>Flushing, hot flush, high blood pressure, low blood pressure,
redness along a vein which is extremely tender when touched</li>
<li>Tightening of the bands of muscle around the airways resulting in
wheezing or coughing, fast breathing rate, shortness of breath that
wakes you up, shortage of oxygen in the blood, abnormal breath sounds,
crackling sounds in the lungs, wheezing, nasal congestion, cough, throat
pain</li>
<li>Belly pain, upper belly pain, bloating, constipation, difficulty
swallowing, dry mouth, indigestion, passing gas, stomach discomfort,
swelling due to build-up of fluid around the belly</li>
<li>Decreased flow of bile, enlarged liver, yellowing of the skin and/or
whites of the eyes, liver injury caused by a drug or chemical, liver
disorder</li>
<li>Abnormal skin tissue, generalised itching, hives, rash of varying
appearance, abnormal skin, red often itchy spots on your arms and legs
and sometimes on the face and the rest of the body</li>
<li>Back pain, pain in an arm or leg, bone pain, muscle pain, muscle
weakness</li>
<li>Loss of kidney function, sudden loss of kidney function</li>
<li>Catheter site pain, injection site complaints (redness, hard lump,
pain, swelling, irritation, rash, hives, leaking of fluid from the
catheter into the tissue), inflammation of vein at injection site</li>
<li>Increased blood pressure and alterations in some laboratory blood
tests (including kidney electrolyte and clotting tests), increased
levels of the medicines you are taking that weaken the immune
system</li>
<li>Chest discomfort, chest pain, feeling of body temperature change,
generally feeling unwell, general pain, swelling of the face, swelling
of the ankles, hands or feet, swelling, tenderness, feeling tired. Side
effects in children and adolescents Very common: may affect more than 1
in 10 people:</li>
<li>Fever Common: may affect up to 1 in 10 people:</li>
<li>Headache</li>
<li>Fast heart beat</li>
<li>Flushing, low blood pressure</li>
<li>Changes in some laboratory blood tests (increased values of some
liver tests)</li>
<li>Itching, rash</li>
<li>Catheter site pain</li>
<li>Chills</li>
<li>Changes in some laboratory blood tests. Reporting of side effects If
you get any side effects, talk to your doctor, nurse or pharmacist. This
includes any possible side effects not listed in this leaflet. You can
also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide
more information on the safety of this medicine.</li>
</ul>
 </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. Do not use
this medicine after the expiry date which is stated on the carton and
the vial (the first two numbers are the month; the next four numbers are
the year). The expiry date refers to the last day of that month. Store
in a refrigerator (2 C to 8 C). Once Cancidas has been prepared, it
should be used straight away. This is because it does not contain any
ingredients to stop the growth of bacteria. Only a trained healthcare
professional who has read the complete directions should prepare the
medicine (please see below Instructions of how to reconstitute and
dilute Cancidas ). Do not throw away any medicines via wastewater or
household waste. Ask your pharmacist how to throw away medicines you no
longer use. These measures will help to protect the environment.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cancidas contains</p>
<ul>
<li>The active substance is caspofungin. Cancidas 50 mg powder for
concentrate for solution for infusion Each vial of Cancidas contains 50
mg of caspofungin. Cancidas 70 mg powder for concentrate for solution
for infusion Each vial of Cancidas contains 70 mg of caspofungin.</li>
<li>The other ingredients are sucrose, mannitol (E421), glacial acetic
acid and sodium hydroxide (please see section 2 What you need to know
before you are given Cancidas). What Cancidas looks like and contents of
the pack Cancidas is a sterile, white to off-white compact powder. Each
pack contains one vial of powder. Marketing Authorisation Holder and
Manufacturer Marketing Authorisation Holder Manufacturer Merck Sharp
&amp; Dohme B.V. Merck Sharp &amp; Dohme B. V. Waarderweg Waarderweg
2031 BN Haarlem 2031 BN Haarlem The Netherlands The Netherlands or
FAREVA Mirabel Route de Marsat-Riom 63963 Clermont-Ferrand Cedex 9
France For any information about this medicinal product, please contact
the local representative of the Marketing Authorisation Holder:
Belgique/Belgi /Belgien MSD Belgium T l/Tel: +32(0)<a
href="mailto:27766dpoc_belux@merck.com">27766dpoc_belux@merck.com</a>
Lietuva UAB Merck Sharp &amp; Dohme Tel.: +370 5 278 02 <a
href="mailto:msd_lietuva@merck.com">msd_lietuva@merck.com</a></li>
</ul>
<p>.: +359 2 819 <a
href="mailto:3info-msdbg@merck.com">3info-msdbg@merck.com</a>
Luxembourg/Luxemburg MSD Belgium T l/Tel: +32(0)<a
href="mailto:27766dpoc_belux@merck.com">27766dpoc_belux@merck.com</a>
esk republika Merck Sharp &amp; Dohme s.r.o. Tel.: +420 233 010 <a
href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a>
Magyarorsz g MSD Pharma Hungary Kft. Tel.: +36 1 888 <a
href="mailto:5hungary_msd@merck.com">5hungary_msd@merck.com</a> Danmark
MSD Danmark ApS Tlf: +45 44 82 40 <a
href="mailto:dkmail@merck.com">dkmail@merck.com</a> Malta Merck Sharp
&amp; Dohme Cyprus Limited Tel.: 8007 4433 (+ 356 99917558) <a
href="mailto:malta_info@merck.com">malta_info@merck.com</a> Deutschland
MSD Sharp &amp; Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) <a
href="mailto:e-mail@msd.de">e-mail@msd.de</a> Nederland Merck Sharp
&amp; Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) <a
href="mailto:medicalinfo.nl@merck.com">medicalinfo.nl@merck.com</a>
Eesti Merck Sharp &amp; Dohme O Tel.: +372 6144 <a
href="mailto:msdeesti@merck.com">msdeesti@merck.com</a> Norge MSD
(Norge) AS Tlf: +47 32 20 73 <a
href="mailto:msdnorge@msd.no">msdnorge@msd.no</a> E MSD . . . . : + 30
210 98 97 <a
href="mailto:dpoc_greece@merck.com">dpoc_greece@merck.com</a> sterreich
Merck Sharp &amp; Dohme Ges.m.b.H. Tel: +43 (0) 1 26 <a
href="mailto:dpoc_austria@merck.com">dpoc_austria@merck.com</a> Espa a
Merck Sharp &amp; Dohme de Espa a, S.A. Tel: +34 91 321 06 <a
href="mailto:msd_info@merck.com">msd_info@merck.com</a> Polska MSD
Polska Sp. z o.o. Tel.: +48 22 549 51 <a
href="mailto:msdpolska@merck.com">msdpolska@merck.com</a> France MSD
France T l: + 33 (0) 1 80 46 40 Portugal Merck Sharp &amp; Dohme, Lda
Tel: +351 21 <a
href="mailto:4465inform_pt@merck.com">4465inform_pt@merck.com</a>
Hrvatska Merck Sharp &amp; Dohme d.o.o. Tel: + 385 1 6611 <a
href="mailto:croatia_info@merck.com">croatia_info@merck.com</a> Rom nia
Merck Sharp &amp; Dohme Romania S.R.L. Tel: + 4021 529 29 <a
href="mailto:msdromania@merck.com">msdromania@merck.com</a> Ireland
Merck Sharp &amp; Dohme Ireland (Human Health) Limited Tel: +353 (0)1 <a
href="mailto:2998medinfo_ireland@merck.com">2998medinfo_ireland@merck.com</a>
Slovenija Merck Sharp &amp; Dohme, inovativna zdravila d.o.o. Tel: + 386
1 <a
href="mailto:5204msd_slovenia@merck.com">5204msd_slovenia@merck.com</a>
sland Vistor hf. S mi: +354 535 7Slovensk republika Merck Sharp &amp;
Dohme, s. r. o. Tel.: +421 2 <a
href="mailto:58282dpoc_czechslovak@merck.com">58282dpoc_czechslovak@merck.com</a>
talia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) <a
href="mailto:medicalinformation.it@msd.com">medicalinformation.it@msd.com</a>
Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0) 9 804 <a
href="mailto:info@msd.fi">info@msd.fi</a></p>
<h2
id="merck-sharp--dohme-cyprus-limited--800-00-673-357-22866700-cyprus_infomerckcom-sverige-merck-sharp--dohme-sweden-ab-tel-46-077-5700medicinskinfomerckcom-latvija-sia-merck-sharp--dohme-latvija-tel-371-67364-msd_lvmerckcom-united-kingdom-northern-ireland-merck-sharp--dohme-ireland-human-health-limited-tel-353-01-2998medinfonimsdcom-this-leaflet-was-last-revised-in-detailed-information-on-this-medicine-is-available-on-the-european-medicines-agency-web-site-httpwwwemaeuropaeu-the-following-information-is-intended-for-medical-or-healthcare-professionals-only-instructions-of-how-to-reconstitute-and-dilute-cancidas-reconstitution-of-cancidas-do-not-use-any-diluents-containing-glucose-as-cancidas-is-not-stable-in-diluents-containing-glucose-do-not-mix-or-co-infuse-cancidas-with-any-other-medicines-as-there-are-no-data-available-on-the-compatibility-of-cancidas-with-other-intravenous-substances-additives-or-medicinal-products-visually-inspect-the-infusion-solution-for-particulate-matter-or-discolouration-cancidas-50-mg-powder-for-concentrate-for-solution-for-infusion-instructions-for-use-in-adult-patients-50-mg-vial-step-1-reconstitution-of-conventional-vials-to-reconstitute-the-powder-bring-the-vial-to-room-temperature-and-aseptically-add-105-ml-of-water-for-injection-the-concentrations-of-the-reconstituted-vials-will-be-52-mgml-the-white-to-off-white-compact-lyophilised-powder-will-dissolve-completely-mix-gently-until-a-clear-solution-is-obtained-reconstituted-solutions-should-be-visually-inspected-for-particulate-matter-or-discolouration-this-reconstituted-solution-may-be-stored-for-up-to-24-hours-at-or-below-25-c-step-2-addition-of-reconstituted-cancidas-to-patient-infusion-solution-diluents-for-the-final-solution-for-infusion-are-sodium-chloride-solution-for-injection-or-lactated-ringer-s-solution-the-solution-for-infusion-is-prepared-by-aseptically-adding-the-appropriate-amount-of-reconstituted-concentrate-as-shown-in-the-table-below-to-a-250-ml-infusion-bag-or-bottle-reduced-volume-infusions-in-100-ml-may-be-used-when-medically-necessary-for-50-mg-or-35-mg-daily-doses-do-not-use-if-the-solution-is-cloudy-or-has-precipitated-50-mg-vial-preparation-of-the-solution-for-infusion-in-adults-dose-volume-of-reconstituted-cancidas-for-transfer-to-intravenous-bag-or-bottle-standard-preparation-reconstituted-cancidas-added-to-250-ml-final-concentration-reduced-volume-infusion-reconstituted-cancidas-added-to-100-ml-final-concentration-50-mg-10-ml-020-mgml">Merck
Sharp &amp; Dohme Cyprus Limited .: 800 00 673 (+357 22866700) <a
href="mailto:cyprus_info@merck.com">cyprus_info@merck.com</a> Sverige
Merck Sharp &amp; Dohme (Sweden) AB Tel: +46 (0)77 <a
href="mailto:5700medicinskinfo@merck.com">5700medicinskinfo@merck.com</a>
Latvija SIA Merck Sharp &amp; Dohme Latvija Tel: +371 67364 <a
href="mailto:msd_lv@merck.com">msd_lv@merck.com</a> United Kingdom
(Northern Ireland) Merck Sharp &amp; Dohme Ireland (Human Health)
Limited Tel: +353 (0)1 <a
href="mailto:2998medinfoNI@msd.com">2998medinfoNI@msd.com</a> This
leaflet was last revised in Detailed information on this medicine is
available on the European Medicines Agency web site: <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>. The
following information is intended for medical or healthcare
professionals only: Instructions of how to reconstitute and dilute
CANCIDAS: Reconstitution of CANCIDAS DO NOT USE ANY DILUENTS CONTAINING
GLUCOSE as CANCIDAS is not stable in diluents containing glucose. DO NOT
MIX OR CO-INFUSE CANCIDAS WITH ANY OTHER MEDICINES, as there are no data
available on the compatibility of CANCIDAS with other intravenous
substances, additives, or medicinal products. Visually inspect the
infusion solution for particulate matter or discolouration. CANCIDAS 50
mg powder for concentrate for solution for infusion INSTRUCTIONS FOR USE
IN ADULT PATIENTS (50 mg vial) Step 1 Reconstitution of conventional
vials To reconstitute the powder bring the vial to room temperature and
aseptically add 10.5 ml of water for injection. The concentrations of
the reconstituted vials will be 5.2 mg/ml. The white to off-white
compact lyophilised powder will dissolve completely. Mix gently until a
clear solution is obtained. Reconstituted solutions should be visually
inspected for particulate matter or discolouration. This reconstituted
solution may be stored for up to 24 hours at or below 25 C. Step 2
Addition of reconstituted CANCIDAS to patient infusion solution Diluents
for the final solution for infusion are: sodium chloride solution for
injection, or lactated Ringer s solution. The solution for infusion is
prepared by aseptically adding the appropriate amount of reconstituted
concentrate (as shown in the table below) to a 250 ml infusion bag or
bottle. Reduced volume infusions in 100 ml may be used, when medically
necessary, for 50 mg or 35 mg daily doses. Do not use if the solution is
cloudy or has precipitated. 50 mg VIAL: PREPARATION OF THE SOLUTION FOR
INFUSION IN ADULTS DOSE* Volume of reconstituted CANCIDAS for transfer
to intravenous bag or bottle Standard preparation (reconstituted
CANCIDAS added to 250 ml) final concentration Reduced volume infusion
(reconstituted CANCIDAS added to 100 ml) final concentration 50 mg 10 ml
0.20 mg/ml</h2>
<h2 id="50-mg-at-reduced-volume-10-ml">50 mg at reduced volume 10
ml</h2>
<h2
id="047-mgml-35-mg-for-moderate-hepatic-impairment-from-one-50-mg-vial-7-ml-014-mgml">0.47
mg/ml 35 mg for moderate hepatic impairment<br />
(from one 50 mg vial) 7 ml 0.14 mg/ml</h2>
<h2
id="35-mg-for-moderate-hepatic-impairment-from-one-50-mg-vial-at-reduced-volume-7-ml">35
mg for moderate hepatic impairment (from one 50 mg vial) at reduced
volume 7 ml</h2>
<p>0.34 mg/ml</p>
<ul>
<li>10.5 ml should be used for reconstitution of all vials. INSTRUCTIONS
FOR USE IN PAEDIATRIC PATIENTS (50 mg vial) Calculation of Body Surface
Area (BSA) for paediatric dosing Before preparation of infusion,
calculate the body surface area (BSA) of the patient using the following
formula: (Mosteller2 Formula) Preparation of the 70 mg/m 2 infusion for
paediatric patients &gt;3 months of age (using a 50-mg vial)</li>
</ul>
<ol type="1">
<li>Determine the actual loading dose to be used in the paediatric
patient by using the patient's BSA (as calculated above) and the
following equation: BSA (m2) X 70 mg/m2 = Loading Dose The maximum
loading dose on Day 1 should not exceed 70 mg regardless of the
patient's calculated dose.</li>
<li>Equilibrate the refrigerated vial of CANCIDAS to room
temperature.</li>
<li>Aseptically add 10.5 ml of water for injection.a This reconstituted
solution may be stored for up to 24 hours at or below 25 C.b This will
give a final caspofungin concentration in the vial of 5.2 mg/ml.</li>
<li>Remove the volume of medicine equal to the calculated loading dose
(Step 1) from the vial. Aseptically transfer this volume (ml)c of
reconstituted CANCIDAS to an IV bag (or bottle) containing 250 ml of 0.9
%, 0.45 %, or 0.225 % Sodium Chloride Injection, or Lactated Ringers
Injection. Alternatively, the volume (ml)c of reconstituted CANCIDAS can
be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium
Chloride Injection or Lactated Ringers Injection, not to exceed a final
concentration of 0.5 mg/ml. This infusion solution must be used within
24 hours if stored at or below 25 C or within 48 hours if stored
refrigerated at 2 to 8 C. Preparation of the 50 mg/m 2 infusion for
paediatric patients &gt;3 months of age (using a 50-mg vial)</li>
<li>Determine the actual daily maintenance dose to be used in the
paediatric patient by using the patient's BSA (as calculated above) and
the following equation: BSA (m2) X 50 mg/m2 = Daily Maintenance Dose The
daily maintenance dose should not exceed 70 mg regardless of the
patient's calculated dose.</li>
<li>Equilibrate the refrigerated vial of CANCIDAS to room temperature. 2
Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med
1987 Oct 22;317(17): 1098 (letter)</li>
<li>Aseptically add 10.5 ml of water for injection.a This reconstituted
solution may be stored for up to 24 hours at or below 25 C.b This will
give a final caspofungin concentration in the vial of 5.2 mg/ml.</li>
<li>Remove the volume of medicine equal to the calculated daily
maintenance dose (Step 1) from the vial. Aseptically transfer this
volume (ml)c of reconstituted CANCIDAS to an IV bag (or bottle)
containing 250 ml of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride
Injection, or Lactated Ringers Injection. Alternatively, the volume
(ml)c of reconstituted CANCIDAS can be added to a reduced volume of 0.9
%, 0.45 %, or 0.225 % Sodium Chloride Injection or Lactated Ringers
Injection, not to exceed a final concentration of 0.5 mg/ml. This
infusion solution must be used within 24 hours if stored at or below 25
C or within 48 hours if stored refrigerated at 2 to 8 C. Preparation
notes: a The white to off-white cake will dissolve completely. Mix
gently until a clear solution is obtained. b Visually inspect the
reconstituted solution for particulate matter or discoloration during
reconstitution and prior to infusion. Do not use if the solution is
cloudy or has precipitated. c CANCIDAS is formulated to provide the full
labelled vial dose (50 mg) when 10 ml is withdrawn from the vial.
CANCIDAS 70 mg powder for concentrate for solution for infusion
INSTRUCTIONS FOR USE IN ADULT PATIENTS (70 mg vial) Step 1
Reconstitution of conventional vials To reconstitute the powder bring
the vial to room temperature and aseptically add 10.5 ml of water for
injection. The concentrations of the reconstituted vials will be: 7.2
mg/ml. The white to off-white compact lyophilised powder will dissolve
completely. Mix gently until a clear solution is obtained. Reconstituted
solutions should be visually inspected for particulate matter or
discolouration. This reconstituted solution may be stored for up to 24
hours at or below 25 C. Step 2 Addition of reconstituted CANCIDAS to
patient infusion solution Diluents for the final solution for infusion
are: sodium chloride solution for injection, or lactated Ringer s
solution. The solution for infusion is prepared by aseptically adding
the appropriate amount of reconstituted concentrate (as shown in the
table below) to a 250 ml infusion bag or bottle. Reduced volume
infusions in 100 ml may be used, when medically necessary, for 50 mg or
35 mg daily doses. Do not use if the solution is cloudy or has
precipitated. 70 mg VIAL: PREPARATION OF THE SOLUTION FOR INFUSION IN
ADULTS DOSE* Volume of reconstituted CANCIDAS for transfer to
intravenous bag or bottle Standard preparation (reconstituted CANCIDAS
added to 250 ml) final concentration Reduced volume infusion
(reconstituted CANCIDAS added to 100 ml) final concentration 70 mg 10 ml
0.28 mg/ml Not Recommended 70 mg (from two 50 mg vials)** 14 ml 0.28
mg/ml Not Recommended DOSE* Volume of reconstituted CANCIDAS for
transfer to intravenous bag or bottle Standard preparation
(reconstituted CANCIDAS added to 250 ml) final concentration Reduced
volume infusion (reconstituted CANCIDAS added to 100 ml) final
concentration 35 mg for moderate hepatic impairment<br />
(from one 70 mg vial) 5 ml 0.14 mg/ml 0.34 mg/ml</li>
</ol>
<ul>
<li>10.5 ml should be used for reconstitution of all vials. **If 70 mg
vial is not available, the 70 mg dose can be prepared from two 50 mg
vials. INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS (70 mg vial)
Calculation of Body Surface Area (BSA) for paediatric dosing Before
preparation of infusion, calculate the body surface area (BSA) of the
patient using the following formula: (Mosteller3 Formula) Preparation of
the 70 mg/m 2 infusion for paediatric patients &gt;3 months of age
(using a 70-mg vial)</li>
</ul>
<ol type="1">
<li>Determine the actual loading dose to be used in the paediatric
patient by using the patient's BSA (as calculated above) and the
following equation: BSA (m2) X 70 mg/m2 = Loading Dose The maximum
loading dose on Day 1 should not exceed 70 mg regardless of the
patient's calculated dose.</li>
<li>Equilibrate the refrigerated vial of CANCIDAS to room
temperature.</li>
<li>Aseptically add 10.5 ml of water for injection.a This reconstituted
solution may be stored for up to 24 hours at or below 25 C.b This will
give a final caspofungin concentration in the vial of 7.2 mg/ml.</li>
<li>Remove the volume of medicine equal to the calculated loading dose
(Step 1) from the vial. Aseptically transfer this volume (ml)c of
reconstituted CANCIDAS to an IV bag (or bottle) containing 250 ml of 0.9
%, 0.45 %, or 0.225 % Sodium Chloride Injection, or Lactated Ringers
Injection. Alternatively, the volume (ml)c of reconstituted CANCIDAS can
be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium
Chloride Injection or Lactated Ringers Injection, not to exceed a final
concentration of 0.5 mg/ml. This infusion solution must be used within
24 hours if stored at or below 25 C or within 48 hours if stored
refrigerated at 2 to 8 C. Preparation of the 50 mg/m 2 infusion for
paediatric patients &gt;3 months of age (using a 70-mg vial)</li>
<li>Determine the actual daily maintenance dose to be used in the
paediatric patient by using the patient's BSA (as calculated above) and
the following equation: BSA (m2) X 50 mg/m2 = Daily Maintenance Dose The
daily maintenance dose should not exceed 70 mg regardless of the
patient's calculated dose.</li>
<li>Equilibrate the refrigerated vial of CANCIDAS to room
temperature.</li>
<li>Aseptically add 10.5 ml of water for injection.a This reconstituted
solution may be stored for up to 24 hours at or below 25 C.b This will
give a final caspofungin concentration in the vial of 7.2 mg/ml.</li>
<li>Remove the volume of medicine equal to the calculated daily
maintenance dose (Step 1) from the vial. Aseptically transfer this
volume (ml)c of reconstituted CANCIDAS to an IV bag (or bottle)
containing 250 ml of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride
Injection, or Lactated Ringers Injection. Alternatively, the volume
(ml)c of reconstituted CANCIDAS can be added to a reduced volume of 0.9
%, 0.45 %, or 0.225 % Sodium Chloride Injection or Lactated Ringers 3
Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med
1987 Oct 22;317(17): 1098 (letter) Injection, not to exceed a final
concentration of 0.5 mg/ml. This infusion solution must be used within
24 hours if stored at or below 25 C or within 48 hours if stored
refrigerated at 2 to 8 C. Preparation notes: a. The white to off-white
cake will dissolve completely. Mix gently until a clear solution is
obtained. b. Visually inspect the reconstituted solution for particulate
matter or discolouration during reconstitution and prior to infusion. Do
not use if the solution is cloudy or has precipitated. c. CANCIDAS is
formulated to provide the full labelled vial dose (70 mg) when 10 ml is
withdrawn from the vial.</li>
</ol>
 </div>"""      



Instance: composition-da-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: CompositionUvEpi
Title: "Composition for cancidas Package Leaflet"
Description:  "Composition for cancidas Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/01/196/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpad129f06143be4f32271a42d5b4c5f85)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cancidas"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen</p>
<ol type="1">
<li>Virkning og anvendelse</li>
<li>Det skal du vide, før du får Cancidas</li>
<li>Sådan får du Cancidas</li>
<li>Bivirkninger</li>
<li>Opbevaring</li>
<li>Pakningsstørrelser og yderligere oplysninger</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning Cancidas indeholder et aktivt stof, der hedder caspofungin.
Det tilhører en gruppe af svampedræbende lægemidler. Anvendelse Cancidas
anvendes til at behandle følgende infektioner hos børn, unge og
voksne:</p>
<ul>
<li><p>alvorlige svampeinfektioner i væv eller organer (kaldet "invasiv
candidiasis"). Denne infektion forårsages af en gærsvamp, som kaldes
Candida. Personer, der kan få denne type infektion, er bl.a. nyopererede
personer og personer med svagt immunforsvar. Feber og kuldegysninger,
som ikke reagerer på antibiotika, er de mest almindelige tegn på denne
type infektion.</p></li>
<li><p>svampeinfektion i næse, bihuler eller lunger (kaldet "invasiv
aspergillosis"), hvis andre behandlinger mod svamp ikke har virket eller
har givet bivirkninger. Denne infektion forårsages af en skimmelsvamp,
som kaldes Aspergillus. Personer, der kan få denne type infektion er
bl.a. personer, der får kemoterapi, er blevet transplanteret, eller hvis
immunforsvar er svagt.</p></li>
<li><p>mistænkt svampeinfektion med feber og nedsat antal hvide
blodlegemer, som ikke reagerer på behandling med antibiotika. Personer
med risiko for at få en svampeinfektion er bl.a. nyopererede personer og
personer med svagt immunforsvar. Sådan virker Cancidas Cancidas svækker
svampecellerne og forhindrer dermed svampen i at vokse. Dette forhindrer
infektionen i at sprede sig og giver kroppens naturlige forsvar en
chance for helt at komme af med infektionen. 32</p></li>
</ul>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Cancidas</p>
<ul>
<li><p>hvis du er allergisk over for caspofungin eller et af de øvrige
indholdsstoffer i Cancidas (angivet i punkt 6). Er du i tvivl, så spørg
lægen, sygeplejersken eller apotekspersonalet, før du får dette
lægemiddel. Advarsler og forsigtighedsregler Kontakt lægen,
sygeplejersken eller apotekspersonalet, før du får Cancidas,
hvis:</p></li>
<li><p>du er allergisk over for anden medicin</p></li>
<li><p>du nogensinde har haft leverproblemer - du skal måske have en
anden dosis af lægemidlet</p></li>
<li><p>du er i behandling med ciclosporin (anvendes til at forhindre
afstødning af et transplanteret organ eller til at undertrykke
immunforsvaret) - da det kan være nødvendigt, at lægen tager ekstra
blodprøver under behandlingen</p></li>
<li><p>du nogensinde har haft andre helbredsmæssige problemer. Kontakt
lægen, sygeplejersken eller apotekspersonalet, hvis noget af ovenstående
gælder for dig (eller du er i tvivl), før du får Cancidas. Cancidas kan
også medføre alvorlige bivirkninger på huden såsom Stevens-Johnsons
syndrom (SJS) og toksisk epidermal nekrolyse (TEN). Brug af anden
medicin sammen med Cancidas Fortæl det altid til lægen eller
apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt
anden medicin eller planlægger at bruge anden medicin. Dette gælder også
medicin, som ikke er købt på recept, f.eks naturlægemidler. Dette
skyldes, at Cancidas kan påvirke måden, andre lægemidler virker på.
Andre lægemidler kan også påvirke måden, Cancidas virker på. Fortæl det
til lægen, sygeplejersken eller apotekspersonalet, hvis du tager et
eller flere af følgende lægemidler:</p></li>
<li><p>ciclosporin eller tacrolimus (medvirker til at forhindre
afstødning af et transplanteret organ eller til at undertrykke
immunforsvaret), da det kan være nødvendigt, at lægen tager ekstra
blodprøver under behandlingen</p></li>
<li><p>medicin mod hiv, f.eks. efavirenz eller nevirapin</p></li>
<li><p>phenytoin eller carbamazepin (anvendes til behandling af
epilepsi)</p></li>
<li><p>dexamethason (et steroid)</p></li>
<li><p>rifampicin (et antibiotikum). Tal med lægen, sygeplejersken eller
apotekspersonalet, hvis noget af ovenstående gælder for dig (eller du er
i tvivl), før du får Cancidas. Graviditet og amning Hvis du er gravid
eller ammer, har mistanke om, at du er gravid, eller planlægger at blive
gravid, skal du spørge din læge til råds, før du får dette
lægemiddel.</p></li>
<li><p>Cancidas er ikke undersøgt hos gravide kvinder. Gravide kvinder
må kun få Cancidas, hvis det skønnes, at fordelene opvejer den mulige
risiko for det ufødte barn.</p></li>
<li><p>Kvinder, der får Cancidas, må ikke amme. Trafik- og
arbejdssikkerhed Der findes ingen oplysninger om, at Cancidas påvirker
evnen til at køre bil eller betjene maskiner. Cancidas indeholder
natrium Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg)
pr. hætteglas, dvs. det er i det væsentlige natriumfrit. 33</p></li>
</ul>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Det er altid sygeplejersken, der vil fremstille og give dig Cancidas.
Du vil få Cancidas:</p>
<ul>
<li><p>en gang dagligt</p></li>
<li><p>ved langsom indgivelse i en blodåre (intravenøs
infusion)</p></li>
<li><p>i løbet af ca. 1 time. Lægen bestemmer behandlingens varighed, og
hvor meget Cancidas du skal have hver dag. Lægen vil kontrollere,
hvordan medicinen virker hos dig. Hvis du vejer mere end 80 kg, skal du
måske have en anden dosis. Brug til børn og unge Dosis til børn og unge
kan være forskellig fra den dosis, der bruges til voksne. Hvis du har
fået for meget Cancidas Lægen bestemmer, hvor meget Cancidas, du har
brug for og hvor lang tid hver dag. Hvis du er bekymret for, om du måske
har fået for meget Cancidas, skal du fortælle det til lægen eller
sygeplejersken med det samme. Hvis du har yderligere spørgsmål om brugen
af denne medicin, skal du spørge lægen, sygeplejersken eller
apotekspersonalet.</p></li>
</ul>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men
ikke alle får bivirkninger. Kontakt straks lægen eller sygeplejersken,
hvis du bemærker en eller flere af følgende bivirkninger - du kan have
brug for omgående lægehjælp:</p>
<ul>
<li><p>udslæt, kløe, varmefølelse, hævelse af ansigt, læber eller svælg
eller vejrtrækningsbesvær - du kan have fået en histaminreaktion på
medicinen.</p></li>
<li><p>vejrtrækningsbesvær med hiven efter vejret eller forværring af
udslæt - du kan have fået en allergisk reaktion på medicinen.</p></li>
<li><p>hoste, alvorlige vejrtrækningsproblemer - hvis du er voksen og
har invasiv aspergillose, kan du få alvorlige vejrtrækningsproblemer,
som kan medføre åndedrætssvigt.</p></li>
<li><p>udslæt, hudafskalning, sår på slimhinder, nældefeber, store
områder med afskalning af huden. Som med al anden receptmedicin, kan
nogle bivirkninger være alvorlige. Spørg lægen om yderligere
information. Andre bivirkninger hos voksne: Almindelige: kan berøre op
til 1 ud af 10 personer:</p></li>
<li><p>Nedsat indhold af hæmoglobin i blodet (det stof, der fører ilt
rundt i blodet), nedsat antal hvide blodlegemer</p></li>
<li><p>Nedsat indhold af albumin (et protein) i blodet, nedsat indhold
(lav koncentration) af kalium i blodet</p></li>
<li><p>Hovedpine</p></li>
<li><p>Årebetændelse</p></li>
<li><p>Åndenød</p></li>
<li><p>Diarré, kvalme eller opkastning</p></li>
<li><p>Ændringer i nogle blodprøver (herunder forhøjede værdier af visse
levertal)</p></li>
<li><p>Kløe, udslæt, hudrødme eller større svedtendens end
normalt</p></li>
<li><p>Ledsmerter 34</p></li>
<li><p>Kuldegysninger, feber</p></li>
<li><p>Kløe på injektionsstedet. Ikke almindelige: kan berøre op til 1
ud af 100 personer:</p></li>
<li><p>Ændringer i nogle blodprøver (herunder blodplader, røde og hvide
blodlegemer samt forstyrrelser i blodets størkningsevne)</p></li>
<li><p>Appetitløshed, stigning i mængden af kropsvæske, forstyrrelser i
kroppens saltbalance, højt indhold af sukker i blodet, lavt indhold af
calcium i blodet, forhøjet calcium i blodet, lavt indhold af magnesium i
blodet, stigning i syreindholdet i blodet</p></li>
<li><p>Desorientering, nervøsitet, søvnløshed</p></li>
<li><p>Svimmelhed, nedsat følelse eller følsomhed (specielt i huden),
rysten, søvnighed, smagsændring, snurrende eller sovende
fornemmelse</p></li>
<li><p>Sløret syn, tåreflåd, hævede øjenlåg, gulfarvning af det hvide i
øjnene</p></li>
<li><p>Fornemmelse af hurtige og uregelmæssige hjerteslag, hurtigt
hjerteslag, uregelmæssigt hjerteslag, unormal hjerterytme,
hjertesvigt</p></li>
<li><p>Ansigtsrødme, hedeture, forhøjet blodtryk, lavt blodtryk, rødme
langs med en blodåre, som er meget øm ved berøring</p></li>
<li><p>Stramning af musklerne omkring luftvejene, som medfører hiven
efter vejret eller hoste, hurtigt åndedræt, åndenød, der får patienten
til at vågne om natten, mangel på ilt i blodet, unormale
vejrtrækningsslyde, rallende lyde i lungerne, hvæsende vejrtrækning,
stoppet næse, hoste, smerter i halsen</p></li>
<li><p>Mavesmerter, smerter i øverste del af maven, oppustethed,
forstoppelse, synkeproblemer, mundtørhed, fordøjelsesproblemer,
luftafgang fra tarmen, mavegener, hævelse pga. ophobning af væske rundt
om maven</p></li>
<li><p>Nedsat mængde galde, forstørret lever, gulfarvning af huden
og/eller det hvide i øjnene, leverskader forårsaget af et lægemiddel
eller kemikalier, leversygdom</p></li>
<li><p>Unormalt hudvæv, udbredt kløe, nældefeber, forskellige former for
udslæt, unormal hud, røde og ofte kløende pletter på arme og ben og af
og til i ansigtet og på resten af kroppen</p></li>
<li><p>Rygsmerter, smerter i arm eller ben, knoglesmerter,
muskelsmerter, muskelsvaghed</p></li>
<li><p>Nedsat nyrefunktion, akut nyresvigt</p></li>
<li><p>Smerter på kateterindstiksstedet, gener på injektionsstedet
(rødme, hård knude, smerter, hævelse, irritation, udslæt, nældefeber,
udsivning af væske fra kateter til væv), betændelse i blodåren på
injektionsstedet</p></li>
<li><p>Forhøjet blodtryk og ændringer i nogle blodprøver (herunder
elektrolytter i nyrerne og koagulationstest), forhøjet koncentration af
de lægemidler, De tager, som svækker immunsystemet</p></li>
<li><p>Gener i brystet, brystsmerter, følelse af temperaturforandring i
kroppen, generel utilpashed, udbredt smerte, hævelse i ansigtet, hævede
ankler, hænder eller fødder, hævelse, ømhed, træthed. Bivirkninger hos
børn og unge Meget almindelige: kan berøre flere end 1 ud af 10
personer:</p></li>
<li><p>Feber Almindelige: kan berøre op til 1 ud af 10
personer:</p></li>
<li><p>Hovedpine</p></li>
<li><p>Hurtige hjerteslag (hurtig puls)</p></li>
<li><p>Ansigtsrødme, lavt blodtryk</p></li>
<li><p>Ændringer i nogle blodprøver (forhøjede værdier af visse
levertal)</p></li>
<li><p>Kløe, udslæt</p></li>
<li><p>Smerter på kateterindstiksstedet</p></li>
<li><p>Kuldegysninger</p></li>
<li><p>Ændringer i nogle blodprøver.</p></li>
</ul>
<p>35 Indberetning af bivirkninger Hvis du oplever bivirkninger, bør du
tale med din læge, apotekspersonalet eller sygeplejersken. Dette gælder
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du
eller dine pårørende kan også indberette bivirkninger direkte til
Lægemiddelstyrelsen via det nationale rapporteringssystem anført i
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at
fremskaffe mere information om sikkerheden af dette lægemiddel.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. Brug ikke lægemidlet efter
den udløbsdato, der står på pakningen og hætteglasset efter EXP (de
første 2 cifre angiver måneden; de næste 4 cifre angiver året).
Udløbsdatoen er den sidste dag i den nævnte måned. Opbevares i køleskab
ved 2-8 C. Når Cancidas er fremstillet, skal det anvendes med det
samme. Dette skyldes, at det ikke indeholder konserveringsmiddel. Kun
uddannet sundhedspersonale, som har læst den fuldstændige vejledning, må
fremstille medicinen (se nedenfor "Brugsvejledning til rekonstitution og
fortynding af Cancidas"). Spørg apotekspersonalet, hvordan du skal
bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide
medicinrester i afløbet, toilettet eller skraldespanden.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cancidas indeholder:</p>
<ul>
<li><p>Aktivt stof: caspofungin. Cancidas 50 mg pulver til koncentrat
til infusionsvæske, opløsning Et hætteglas Cancidas indeholder 50 mg
caspofungin. Cancidas 70 mg pulver til koncentrat til infusionsvæske,
opløsning Et hætteglas Cancidas indeholder 70 mg caspofungin.</p></li>
<li><p>Øvrige indholdsstoffer: saccharose, mannitol (E421), eddikesyre
og natriumhydroxid (se punkt</p></li>
</ul>
 </div>"""      



Instance: composition-pt-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: CompositionUvEpi
Title: "Composition for cancidas Package Leaflet"
Description:  "Composition for cancidas Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/01/196/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpad129f06143be4f32271a42d5b4c5f85)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cancidas"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #pt
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. FOLHETO INFORMATIVO"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. FOLHETO INFORMATIVO"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Folheto informativo: Informação para o utilizador"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Folheto informativo: Informação para o utilizador"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "O que contém este folheto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "O que contém este folheto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que contém este folheto</p>
<ol type="1">
<li>O que é Cancidas e para que é utilizado</li>
<li>O que precisa de saber antes de utilizar Cancidas</li>
<li>Como utilizar Cancidas</li>
<li>Efeitos indesejáveis possíveis</li>
<li>Como conservar Cancidas</li>
<li>Conteúdo da embalagem e outras informações</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. O que é cancidas e para que é utilizado"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. O que é cancidas e para que é utilizado"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que é Cancidas Cancidas contém um medicamento chamado caspofungina.
Este medicamento pertence a um grupo de medicamentos chamados
antifúngicos. Para que é utilizado Cancidas Cancidas é utilizado para
tratar as seguintes infeções em crianças, adolescentes e adultos:</p>
<ul>
<li><p>Infeções fúngicas graves nos seus tecidos ou órgãos (chamada
“candidíase invasiva"). Esta infeção é causada por um fungo (levedura)
chamada Candida. As pessoas que foram submetidas recentemente a uma
operação e as que têm um sistema imunitário mais fraco podem ter este
tipo de infeção. Os sintomas mais frequentes deste tipo de infeções são
febre e arrepios que não respondem a antibióticos.</p></li>
<li><p>Infeções fúngicas no nariz, seios nasais ou pulmões (chamada
“aspergilose invasiva"), se outros tratamentos antifúngicos não tiveram
efeito, ou lhe tiverem causado efeitos indesejáveis. Esta infeção é
causa por um fungo chamado Aspergillus. As pessoas que estão a fazer
quimioterapia, pessoas que foram submetidas a um transplante e os que
têm um sistema imunitário mais fraco podem ter este tipo de
infeção.</p></li>
<li><p>Suspeite de infeção fúngica se tiver febre e baixo número de
glóbulos brancos, que não melhorou com o tratamento com antibióticos.
Pessoas em risco de ter uma infeção fúngica incluem as que foram
recentemente operadas ou que têm um sistema imunitário mais fraco. Como
funciona o Cancidas O Cancidas torna as células fúngicas frágeis e evita
o correto crescimento dos fungos. Isto evita que a infeção se dissemine
e permite que as defesas naturais do organismo consigam eliminar a
infeção.</p></li>
</ul>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. O que precisa de saber antes de tomar cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. O que precisa de saber antes de tomar cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Não use Cancidas</p>
<ul>
<li><p>se tem alergia à caspofungina ou a qualquer outro componente
deste medicamento (indicados na secção 6). 34 Se não tem a certeza, fale
com o seu médico, farmacêutico ou enfermeiro antes de lhe ser
administrado o medicamento. Advertências e precauções Fale com o seu
médico, farmacêutico ou enfermeiro antes de utilizar Cancidas
se:</p></li>
<li><p>for alérgico a qualquer outro medicamento</p></li>
<li><p>alguma vez teve problemas no fígado - pode precisar de uma dose
diferente deste medicamento</p></li>
<li><p>já está a tomar ciclosporina (utilizado para ajudar na prevenção
da rejeição após um transplante de órgão ou para suprimir o seu sistema
imunitário) pois o seu médico pode precisar de realizar testes
adicionais ao seu sangue durante o tratamento.</p></li>
<li><p>teve qualquer outro problema médico. Se alguma das situações
anteriores se aplicar a si (ou se não tem a certeza), fale com o seu
médico, farmacêutico ou enfermeiro antes de lhe ser administrado
Cancidas. Cancidas pode também causar Reações Adversas Graves na Pele
tais como Síndrome de Stevens-Johnson (SSJ) e necrólise epidérmica
tóxica (NET). Outros medicamentos e Cancidas Por favor, informe o seu
médico, farmacêutico ou enfermeiro se estiver a tomar, tiver tomado
recentemente, ou se vier a tomar outros medicamentos. Isto inclui
medicamentos que obteve sem receita médica ou medicamentos à base de
plantas. Isto porque Cancidas pode afetar o modo como atuam outros
medicamentos. Há também medicamentos que podem alterar o efeito de
Cancidas. Informe o seu médico, farmacêutico ou enfermeiro se está a
tomar alguns dos seguintes medicamentos:</p></li>
<li><p>ciclosporina ou tacrolímus (utilizado para ajudar na prevenção da
rejeição de um órgão transplantado ou para suprimir o sistema
imunitário) pois o seu médico pode precisar de realizar testes
adicionais ao sangue durante o tratamento.</p></li>
<li><p>alguns medicamentos anti-VIH tais como efavirenz ou
nevirapina</p></li>
<li><p>fenitoína ou carbamazepina (utilizados para tratar crises
convulsivas)</p></li>
<li><p>dexametasona (um corticosteroide)</p></li>
<li><p>rifampicina (um antibiótico) Se algum dos medicamentos anteriores
se aplica a si (ou se não tem a certeza), fale com o seu médico,
farmacêutico ou enfermeiro antes de lhe ser administrado Cancidas.
Gravidez e amamentação Se está grávida ou a amamentar ou se pensa estar
grávida, consulte o seu médico antes de tomar qualquer
medicamento.</p></li>
<li><p>Cancidas não foi estudado em mulheres grávidas. Só deve ser usado
na gravidez se o potencial benefício justificar o potencial risco para o
bebé que irá nascer.</p></li>
<li><p>As mulheres a quem é administrado Cancidas não devem amamentar.
Condução de veículos e utilização de máquinas Não há informação que
sugira que Cancidas afete a sua capacidade para conduzir ou utilizar
máquinas. Cancidas contém sódio Este medicamento contém menos do que 1
mmol (23 mg) de sódio por frasco para injetáveis ou seja, é praticamente
“isento de sódio"</p></li>
</ul>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Como tomar cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Como tomar cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cancidas será sempre preparado e administrado por um profissional de
saúde. 35 Ser-lhe-á administrado Cancidas:</p>
<ul>
<li><p>uma vez por dia</p></li>
<li><p>por injeção lenta numa veia (perfusão intravenosa)</p></li>
<li><p>durante aproximadamente 1 hora O seu médico determinará a duração
do tratamento, assim como a quantidade de Cancidas que lhe será dada por
dia. O seu médico irá vigiar como o medicamento funciona consigo. Se o
seu peso for superior a 80 kg, pode necessitar de uma dose diferente.
Crianças e adolescentes A dose para crianças e adolescentes pode diferir
da dose utilizada em adultos. Se lhe for administrado mais Cancidas do
que deveria O seu médico irá vigiar a cada dia a dose de Cancidas de que
necessita e durante quando tempo. Se está preocupado por achar que pode
ter-lhe sido administrada uma quantidade excessiva de Cancidas, informe
imediatamente o seu médico ou enfermeiro. Caso ainda tenha dúvidas sobre
a utilização deste medicamento, fale com o seu médico, farmacêutico ou
enfermeiro.</p></li>
</ul>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Efeitos indesejáveis possíveis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Efeitos indesejáveis possíveis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Como todos os medicamentos, este medicamento pode causar efeitos
indesejáveis, embora estes não se manifestem em todas as pessoas. Fale
imediatamente com o seu médico ou enfermeiro se sentir algum dos
seguintes efeitos adversos - poderá precisar de tratamento médico
urgente:</p>
<ul>
<li><p>erupções na pele, comichão, sensação de calor, inchaço da face,
lábios ou garganta ou dificuldade em respirar - poderá estar a ter uma
reação de libertação de histamina ao medicamento.</p></li>
<li><p>respiração difícil e ruidosa ou agravamento de erupções da pele
já existentes - poderá estar a ter uma reação alérgica ao
medicamento.</p></li>
<li><p>tosse, dificuldades respiratórias graves - se for adulto e tem
aspergilose invasiva, poderá estar a ter um problema respiratório grave
que pode resultar em insuficiência respiratória.</p></li>
<li><p>erupção na pele, descamação da pele, feridas das membranas
mucosas, urticária, extensa zona de descamação da pele. Como com
qualquer outro medicamento sujeito a receita médica, alguns efeitos
indesejáveis poderão ser graves. Peça ao seu médico mais informações.
Outros efeitos adversos em adultos incluem: Frequentes: podem afetar até
1 em cada 10 pessoas:</p></li>
<li><p>Diminuição da hemoglobina (redução da substância que transporta
oxigénio no sangue), diminuição do número de glóbulos brancos</p></li>
<li><p>Diminuição de albumina (um tipo de proteína) no seu sangue,
diminuição da quantidade de potássio ou níveis baixos de potássio no
sangue</p></li>
<li><p>Dor de cabeça</p></li>
<li><p>Inflamação da veia</p></li>
<li><p>Dificuldade em respirar</p></li>
<li><p>Diarreia, náuseas ou vómitos</p></li>
<li><p>Alterações dos resultados de algumas análises laboratoriais ao
sangue (incluindo valores aumentados de algumas análises ao
fígado)</p></li>
<li><p>Comichão, erupções na pele, vermelhidão da pele ou suar mais que
o habitual</p></li>
<li><p>Dor nas articulações 36</p></li>
<li><p>Arrepios, febre</p></li>
<li><p>Comichão no local de injeção Pouco frequentes: podem afetar até 1
em 100 pessoas:</p></li>
<li><p>Alterações dos resultados de algumas análises laboratoriais ao
sangue (incluindo alterações da coagulação sanguínea, plaquetas,
glóbulos vermelhos e glóbulos brancos)</p></li>
<li><p>Perda de apetite, aumento do fluido corporal, desequilíbrio dos
níveis de sal no organismo, aumento da quantidade de açúcar no sangue,
diminuição da quantidade de cálcio no sangue, aumento da quantidade de
cálcio no sangue, diminuição da quantidade de magnésio no sangue,
aumento da acidez do sangue</p></li>
<li><p>Desorientação, nervosismo, incapacidade de dormir</p></li>
<li><p>Sensação de tonturas, diminuição dos sentidos ou da sensibilidade
(especialmente na pele), tremores, sonolência, perturbações do paladar,
formigueiro ou dormência</p></li>
<li><p>Visão turva, lacrimejo aumentado, pálpebra inchada,
amarelecimento da zona branca dos olhos</p></li>
<li><p>Sensação de batimento acelerado ou irregular do coração,
batimento cardíaco rápido, batimento irregular do coração, ritmo do
coração anormal, falência do coração</p></li>
<li><p>Vermelhidão da face, afrontamentos, aumento da pressão arterial,
diminuição da pressão arterial, vermelhidão ao longo da veia que está
extremamente sensível ao toque</p></li>
<li><p>Contração dos feixes musculares que rodeiam as vias
respiratórias, resultando em pieira ou tosse, ritmo respiratório
aumentado, falta de ar que o acorda durante o sono, diminuição de
oxigénio no sangue, sons respiratórios anormais, fervores nos pulmões,
pieira, nariz entupido, tosse, dor de garganta</p></li>
<li><p>Dor de barriga, dor na zona superior da barriga, inchaço,
obstipação, dificuldade em engolir, boca seca, indigestão, gases,
desconforto no estômago, inchaço por acumulação de líquidos na
barriga</p></li>
<li><p>Diminuição do fluxo de bílis, fígado aumentado, coloração amarela
da pele e/ou da zona branca dos olhos, danos no fígado causados por uma
droga ou químico, perturbações do funcionamento do fígado</p></li>
<li><p>Alterações da pele, comichão generalizada, urticária, erupções na
pele de aparências variadas, pele anormal, zonas vermelhas e
frequentemente com comichão nos seus braços e pernas e, por vezes, na
face e resto do corpo</p></li>
<li><p>Dor nas costas, dor num braço ou perna, dor óssea, dor muscular,
fraqueza muscular</p></li>
<li><p>Perda da função renal, perda súbita da função renal</p></li>
<li><p>Dor no local do cateter, queixas no local de injeção
(vermelhidão, corrimento, dor, inchaço, irritação, erupção cutânea,
comichão, vazamento de líquido do cateter para o tecido), inflamação da
veia no local de injeção</p></li>
<li><p>Aumento da pressão arterial e alterações dos resultados de
algumas análises laboratoriais ao sangue (incluindo aos eletrólitos dos
rins e nos testes de coagulação), aumento dos níveis de medicamentos que
enfraquecem o sistema imunitário</p></li>
<li><p>Desconforto no peito, dor no peito, sensação de alteração da
temperatura corporal, sensação de mal-estar generalizado, dor geral,
face inchada, inchaço dos tornozelos, mãos ou pés, sensibilidade,
fadiga. Efeitos indesejáveis em crianças e adolescentes Muito
frequentes: podem afetar mais de 1 em 10 pessoas:</p></li>
<li><p>Febre Frequentes: podem afetar até 1 em 10 pessoas:</p></li>
<li><p>Dor de cabeça</p></li>
<li><p>Batimento acelerado do coração</p></li>
<li><p>Vermelhidão na face, tensão arterial baixa</p></li>
<li><p>Alterações dos resultados de algumas análises laboratoriais ao
sangue (valores aumentados de algumas análises ao fígado)</p></li>
<li><p>Comichão, erupções na pele</p></li>
<li><p>Dor no local de inserção do cateter 37</p></li>
<li><p>Arrepios</p></li>
<li><p>Alterações dos resultados de algumas análises laboratoriais ao
sangue Comunicação de efeitos indesejáveis Se tiver quaisquer efeitos
indesejáveis, incluindo possíveis efeitos indesejáveis não indicados
neste folheto, fale com o seu médico, enfermeiro ou farmacêutico. Também
poderá comunicar efeitos indesejáveis diretamente através do sistema
nacional de notificação mencionado no Apêndice V. Ao comunicar efeitos
indesejáveis, estará a ajudar a fornecer mais informações sobre a
segurança deste medicamento.</p></li>
</ul>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Como conservar cancidas"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Como conservar cancidas"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Manter este medicamento fora da vista e do alcance das crianças. Não
utilize este medicamento após o prazo de validade impresso na embalagem
exterior e no frasco (os dois primeiros algarismos são o mês; os quatro
algarismos seguintes são o ano). O prazo de validade corresponde ao
último dia do mês indicado. Conservar no frigorífico (2 ºC a 8 ºC). Uma
vez preparado, Cancidas deve ser utilizado imediatamente. Isto porque
não contém nenhum componente que para o crescimento bacteriano. Só um
profissional de saúde experiente que tenha lido as instruções na sua
totalidade pode preparar este medicamento (ver a seguir “Instruções para
a reconstituição e diluição do Cancidas"). Não deite fora quaisquer
medicamentos na canalização ou no lixo doméstico. Pergunte ao seu
farmacêutico como deitar fora os medicamentos que já não utiliza. Estas
medidas ajudarão a proteger o ambiente.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Conteúdo da embalagem e outras informações"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Conteúdo da embalagem e outras informações"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qual a composição de Cancidas</p>
<ul>
<li><p>A substância ativa é a caspofungina. Cancidas 50 mg pó para
concentrado para solução para perfusão Cada frasco para injetáveis de
Cancidas contém 50 mg de caspofungina. Cancidas 50 mg pó para
concentrado para solução para perfusão Cada frasco para injetáveis de
Cancidas contém 70 mg de caspofungina.</p></li>
<li><p>Os outros componentes são: sacarose, manitol (E421), ácido
acético glacial e hidróxido de sódio (por favor consulte secção</p></li>
</ul>
 </div>"""      





                    
Instance: bundlepackageleaflet-en-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cancidas Package Leaflet for language en"
Description: "ePI document Bundle for cancidas Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-ad129f06143be4f32271a42d5b4c5f85"
* entry[0].resource = composition-en-ad129f06143be4f32271a42d5b4c5f85

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpad129f06143be4f32271a42d5b4c5f85"
* entry[=].resource = mpad129f06143be4f32271a42d5b4c5f85
                            
                    
Instance: bundlepackageleaflet-da-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cancidas Package Leaflet for language da"
Description: "ePI document Bundle for cancidas Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-ad129f06143be4f32271a42d5b4c5f85"
* entry[0].resource = composition-da-ad129f06143be4f32271a42d5b4c5f85

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpad129f06143be4f32271a42d5b4c5f85"
* entry[=].resource = mpad129f06143be4f32271a42d5b4c5f85
                            
                    
Instance: bundlepackageleaflet-pt-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cancidas Package Leaflet for language pt"
Description: "ePI document Bundle for cancidas Package Leaflet for language pt"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #pt

// Composition
* entry[0].fullUrl = "Composition/composition-pt-ad129f06143be4f32271a42d5b4c5f85"
* entry[0].resource = composition-pt-ad129f06143be4f32271a42d5b4c5f85

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpad129f06143be4f32271a42d5b4c5f85"
* entry[=].resource = mpad129f06143be4f32271a42d5b4c5f85
                            
                    



Instance: mpad129f06143be4f32271a42d5b4c5f85
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product CANCIDAS 50 mg powder for concentrate for solution for infusion"
Description: "CANCIDAS 50 mg powder for concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/01/196/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "CANCIDAS 50 mg powder for concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: ad129f06143be4f32271a42d5b4c5f85ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "cancidas"

* status = #current
* mode = #working

* title = "List of all ePIs associated with cancidas"

* subject = Reference(mpad129f06143be4f32271a42d5b4c5f85)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#cancidas "cancidas"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-ad129f06143be4f32271a42d5b4c5f85) // cancidas en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-ad129f06143be4f32271a42d5b4c5f85) // cancidas da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-pt-ad129f06143be4f32271a42d5b4c5f85) // cancidas pt
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "pt"




Instance: List-ad129f06143be4f32271a42d5b4c5f85
InstanceOf: List
Description: "ePI document List for cancidas Package Leaflets"

* insert ad129f06143be4f32271a42d5b4c5f85ListRuleset
    